Literature DB >> 25034964

Inhibition of islet amyloid polypeptide fibril formation by selenium-containing phycocyanin and prevention of beta cell apoptosis.

Xiaoling Li1, Lijuan Ma1, Wenjie Zheng1, Tianfeng Chen2.   

Abstract

Human islet amyloid polypeptide (hIAPP) fibril is the major constituent of amyloid deposits in pancreatic islets of type 2 diabetes. Misfolding and hIAPP fibril formation are thought to be important in the pathogenesis of diabetes. Studies have showed that selenium-containing phycocyanin (Se-PC) inhibited the fibrillation of hIAPP to form nanoscale particles, which is mainly by interfering with the combination between hIAPP. Small nanoscale oligomers tended to grow into larger nanoparticles and the size of nanoparticles increased with the incubation time. By interfering with the fibrillation of hIAPP and altering the structure, Se-PC alleviated hIAPP-induced cell apoptosis. Meantime, generation of ROS produced during the fibrillation process was inhibited, which was proposed to be the main factor for the hIAPP-cytotoxicity in beta cells. Taken together, Se-PC inhibited hIAPP fibrillation, thus suppressed the formation of ROS to show protective effect on hIAPP mediated cell apoptosis. Our studies provide useful information for our understanding of the interaction mechanisms of Se-PC on hIAPP structure and protective mechanisms on hIAPP cytotoxicity, presenting useful candidate for anti-diabetes drug development.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diabetes; Fibrillation; Islet amyloid polypeptide; Nanoparticle; Phycocyanin

Mesh:

Substances:

Year:  2014        PMID: 25034964     DOI: 10.1016/j.biomaterials.2014.06.056

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

1.  Probing the binding affinity of amyloids to reduce toxicity of oligomers in diabetes.

Authors:  Mohamed Raef Smaoui; Henri Orland; Jérôme Waldispühl
Journal:  Bioinformatics       Date:  2015-03-15       Impact factor: 6.937

2.  Targeted delivery of paclitaxel by functionalized selenium nanoparticles for anticancer therapy through ROS-mediated signaling pathways.

Authors:  Guifang Gong; Bailing Fu; Caixin Ying; Zhiqin Zhu; Xiaoqian He; Yingying Li; Zhuanxing Shen; Qingshan Xuan; Yanqing Huang; Yan Lin; Yinghua Li
Journal:  RSC Adv       Date:  2018-11-30       Impact factor: 4.036

3.  Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways.

Authors:  Yinghua Li; Zhengfang Lin; Min Guo; Mingqi Zhao; Yu Xia; Changbing Wang; Tiantian Xu; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2018-04-03

4.  Dual effect of PEG-PE micelle over the oligomerization and fibrillation of human islet amyloid polypeptide.

Authors:  Xiaocui Fang; Maryam Yousaf; Qunxing Huang; Yanlian Yang; Chen Wang
Journal:  Sci Rep       Date:  2018-03-13       Impact factor: 4.379

5.  Lipid accelerating the fibril of islet amyloid polypeptide aggravated the pancreatic islet injury in vitro and in vivo.

Authors:  Xiao-Dan Mo; Li-Ping Gao; Qing-Jun Wang; Jie Yin; Yu-Hong Jing
Journal:  Lipids Health Dis       Date:  2018-03-09       Impact factor: 3.876

6.  Selenium nanoparticles inhibited H1N1 influenza virus-induced apoptosis by ROS-mediated signaling pathways.

Authors:  Xia Liu; Danyang Chen; Jingyao Su; Ruilin Zheng; Zhihui Ning; Mingqi Zhao; Bing Zhu; Yinghua Li
Journal:  RSC Adv       Date:  2022-01-31       Impact factor: 3.361

Review 7.  Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus.

Authors:  Lucie Caillon; Anais R F Hoffmann; Alexandra Botz; Lucie Khemtemourian
Journal:  J Diabetes Res       Date:  2015-11-09       Impact factor: 4.011

8.  ROS‑mediated autophagy through the AMPK signaling pathway protects INS‑1 cells from human islet amyloid polypeptide‑induced cytotoxicity.

Authors:  Guanghao Xia; Tiehong Zhu; Xiaotong Li; Yujing Jin; Jing Zhou; Jinfeng Xiao
Journal:  Mol Med Rep       Date:  2018-07-03       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.